Over the past year, there has been a simmering dispute between hospitals and pharmaceutical companies over the 340B drug pricing program. This week, the United States Department of Health and Human Services weighed in strongly on the side of the ...
As nurses’ critical role in health care rapidly evolves, they are becoming harder to find. A 2018 study published in the American Journal of Medical Quality estimated a shortage of 510,394 registered nurses by 2030. This shortage is driven by both ...
Recruiting and retaining patients for clinical trials is one of the most intractable problems facing clinical research organizations and biopharma companies. CVS thinks that its thousands of retail locations could be the answer. We also look at Food and Drug ...
The U.S. Food and Drug Administration’s approval of the Alzheimer’s drug, aducanumab, ushered in both a likely blockbuster for developer Biogen and sparked a debate both within the biopharma industry and among health care providers. We also look at a ...
Given the high volume of mergers and acquisitions in life sciences, changes in the leadership and focus of the Federal Trade Commission will be closely watched in the coming months as scrutiny could shift to the technology industry. We examine ...
Deep brain stimulation (DBS) is a remarkable tool where a small device is implanted in the body with leads carefully placed at critical spots in the brain. The tool can help manage symptoms of some neurodegenerative diseases. Now, a new ...
Each week we highlight five things affecting the life sciences industry. Here’s the latest. In 2024, biopharma companies prioritized manufacturing capabilities to attract investors and ensure scalability, as reported by BioSpace. Major companies are significantly investing in manufacturing infrastructure to ...
Diabetes effects more than 10% of the U.S. population and brings with it the risk of serious complications, high health care costs and daily difficulties for patients that are afflicted with it. This week we look at the potential of ...
Each week we highlight five things affecting the life sciences industry. Here’s the latest. President-elect Donald Trump’s nomination of Andrew Ferguson and Mark Meador to the Federal Trade Commission signals a potential shift toward a more business-friendly antitrust approach, focusing ...
The health care and life sciences industries could be facing significant changes under a second Trump administration. From the prospect of new tariffs to the likelihood that the BIOSECURE Act will be enacted, companies are scrambling to adjust to what ...